Increased risk weighs on SINO BIOPHARMCL, penalising its rating down to Slightly Negative
The independent financial analyst theScreener just lowered the general evaluation of SINO BIOPHARMCL (HK), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date January 18, 2022, the closing price was HKD 6.05 and its target price was estimated at HKD 4.71.Sino Biopharmaceutical is an investment holding company and an integrated pharmaceutical enterprise. Through its subsidiaries, Co. is engaged in the research and development, production and sale of a range of Chinese medicines and chemical medicines. Co.'s segments include: the Chinese medicines and chemical medicines, which comprises the manufacture, sale and distribution of Chinese medicine products and western medicine products; the investment, which is engaged in long term investments; and the others, which comprises of Co.'s research and development sector that provides services to third parties related healthcare and hospital business.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.